HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Sanitizer Contaminations Drop In US As Auxiliary Manufacturers Stop Production

Executive Summary

"Fewer people are manufacturing the products ... That seems to be a sort of a natural reaction to I think the decreased consumer demand," says Donald Ashley, compliance chief in FDA’s drug center.

You may also be interested in...

US FDA Recommends Tests, Documentation To Show Benzene No Higher Than 2PPM In Drugs

CDER says guidance needed to help facilitate and expedite reformulating drug products which use carbomers manufactured with benzene, a human carcinogen, so that no more than 2 parts per million of the substance is present.

Tighter Testing New Normal For US OTC Sanitizer Firms Due To Contaminations During Pandemic

With higher demand a norm, OTC sanitizer firms should do the same with scrutiny of their supplies of alcohol and other ingredients. “The market itself will always be much higher than a pre-COVID level as it’s a consumer product that is going to be used on a more regular basis,” says Ed Wyszumiala, head of US Pharmacopeia’s verification program.

US FDA Testing Finds Consumer Health Market Problems, But It Can’t Test Entire Marketplace

CDER compliance office director Donald Ashley offers a cautionary note to temper expectations for the FDA’s enforcement in the supplement sector. “We continue to warn the public about products very often sold as dietary supplements that contain hidden drugs,” he says.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts